{"id":"W1983150990","doi":"10.1016/j.ygyno.2013.04.011","title":"A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma","year":2013,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Onyx Pharmaceuticals; Bayer HealthCare","keywords":"Medicine; Sorafenib; Front line; Oncology; Ovarian carcinoma; Internal medicine; Randomized controlled trial; Ovarian cancer; Gynecology; Hepatocellular carcinoma; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001741668,0.001645421,0.003275118,0.0004643611,0.0004378886,0.001094618,0.001100471,0.001363562,0.007304742],"category_scores_gemma":[0.001687731,0.0006874508,0.001740181,0.0004176877,0.0014019,0.001464044,0.0005161237,0.003391595,0.001121794],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001019454,"about_ca_system_score_gemma":0.001236309,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001068736,"about_ca_topic_score_gemma":0.002044386,"domain_scores_codex":[0.9994462,0.0002619604,0.00002854991,0.0001156374,0.00003506653,0.0001125425],"domain_scores_gemma":[0.9989502,0.0002452403,0.0001772064,0.0001482866,0.00005636091,0.0004227632],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.979816,0.004035993,0.000581727,0.0002154081,0.0005101928,0.00002799199,0.00004367221,0.0004204551,0.001753987,0.00007298112,0.0006779972,0.01184356],"study_design_scores_gemma":[0.9549715,0.04255804,0.001172205,0.00001140974,0.000198641,0.0000306641,0.00002007054,0.0003505561,0.0002306888,0.0001083901,0.0003395981,0.00000834299],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9930862,0.001922325,0.0004055689,0.0006303394,0.0003973382,0.001657614,0.0006530786,0.00009733422,0.001150407],"genre_scores_gemma":[0.9906803,0.001160325,0.001074399,0.0007428747,0.0003110152,0.002268901,0.00132639,0.00002946747,0.002406207],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007304742,"threshold_uncertainty_score":0.02443677,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03282044406175986,"score_gpt":0.3211219546542424,"score_spread":0.2883015105924825,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}